Most Clicked StoriesMore >


Janssen ordered to pay $2.5M in damages over Risperdal case

FDLI SmartBrief | Feb 26, 2015

A Philadelphia jury ordered Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to pay $2.5 million in damages to a 20-year old man who developed gynecomastia after taking the firm's antipsychotic drug Risperdal when he was a child. Janssen's director of product communication, Robyn Reed Frenze, spoke out against the verdict, saying the drug's potential side effects were clearly stated on the product label.  This case is the first of over 1,200 Risperdal-related lawsuits in Philadelphia. Philadelphia Inquirer, The (02/25)


Firm widens recall of pet food products over salmonella, listeria risks

FDLI SmartBrief | Feb 20, 2015

More than 3K bottles of levetiracetam recalled by firm

FDLI SmartBrief | Feb 24, 2015

U.S. falls short on antibiotic development to fight superbugs

FDLI SmartBrief | Feb 23, 2015

Judge strikes down prescription drug importation law in Maine

FDLI SmartBrief | Feb 25, 2015

FDA steps up oversight of compounding pharmacies

FDLI SmartBrief | Feb 23, 2015

FTC cracks down on melanoma risk-detection apps with unsupported claims

FDLI SmartBrief | Feb 25, 2015

Nutrition committee urges Americans to cut back on sugar

FDLI SmartBrief | Feb 20, 2015

FDA proposes adverse-event reporting guidance for cellular, tissue products

FDLI SmartBrief | Feb 20, 2015

Risk of potentially deadly infection prompts warning over reusable endoscopes

FDLI SmartBrief | Feb 20, 2015


Find FDLI SmartBrief Issues by Date:



FDLI News More >


Hot-topic FDLI webinars coming soon

FDLI SmartBrief | Feb 26, 2015

The largest legal conference for the food and drug law community is less than 2 months away!

FDLI SmartBrief | Feb 26, 2015

What were the top food and drug cases of 2014? Which cases should you watch in 2015? Attend the FDLI Annual Conference to find out

FDLI SmartBrief | Feb 25, 2015

Follow FDLI on Twitter

FDLI SmartBrief | Feb 25, 2015

Save the date for our next Introductory Drug Law and Regulation Course

FDLI SmartBrief | Feb 24, 2015




Sign up for FDLI SmartBrief



Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more

Recent Poll view more polls


What affect do you think this year's media focus on imported drug, food and medical device product safety will have in 2010?

Chart.